French drugmaker Sanofi-Aventis said Wednesday it received European approval to sell the combination blood thinner DuoPlavin/DuoCover it developed with Bristol-Myers Squibb Co.
The drug combines aspirin and the blood thinner Plavix, the world's second best-selling drug, to ease the daily pill burden in patients, the companies said in a statement.
It aims to treat blood clots in patients with heart conditions, including some who have received stents, or tubes used to prop open arteries after they have been cleared of fatty plaque.
A spokeswoman for New York-based Bristol-Myers said the companies have no plans to sell the drug in the U.S.
Bristol-Myers shares fell 10 cents to $26.69 in Wednesday morning trading, while American shares of Sanofi-Aventis fell 76 cents to $37.39.